GC-101

N/A

Report date: 2026/03/11 20:02:12

Base Information

Drug NameGC-101
Drug Alias NameGC-101AAV9-SMN
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionGene modulatorsNAD-dependent protein deacetylase sirtuin-3, mitochondrial modulators
TargetsNAD-dependent protein deacetylase sirtuin-3, mitochondrial
Therapy Area/IndicationsSpinal Muscular Atrophies of ChildhoodMuscular Atrophy, Spinal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing GeneCradle Gene Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing GeneCradle Gene Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSpinal Muscular Atrophies of ChildhoodMuscular Atrophy, Spinal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A